Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers.

Chatterjee N, Pazarentzos E, Mayekar MK, Gui P, Allegakoen DV, Hrustanovic G, Olivas V, Lin L, Verschueren E, Johnson JR, Hofree M, Yan JJ, Newton BW, Dollen JV, Earnshaw CH, Flanagan J, Chan E, Asthana S, Ideker T, Wu W, Suzuki J, Barad BA, Kirichok Y, Fraser JS, Weiss WA, Krogan NJ, Tulpule A, Sabnis AJ, Bivona TG.

Cell Rep. 2019 Aug 27;28(9):2317-2330.e8. doi: 10.1016/j.celrep.2019.07.063.

2.

Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry.

Lansigan F, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.

Acta Haematol. 2019 Jul 17:1-11. doi: 10.1159/000500666. [Epub ahead of print]

PMID:
31315113
3.

The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study.

Park SI, Horwitz SM, Foss FM, Pinter-Brown LC, Carson KR, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Shustov AR; COMPLETE Investigators.

Cancer. 2019 May 1;125(9):1507-1517. doi: 10.1002/cncr.31861. Epub 2019 Jan 29. Erratum in: Cancer. 2019 Nov 1;125(21):3893.

PMID:
30694529
4.

Surveillance Screening in Li-Fraumeni Syndrome: Raising Awareness of False Positives.

Kumar P, Gill RM, Phelps A, Tulpule A, Matthay K, Nicolaides T.

Cureus. 2018 Apr 24;10(4):e2527. doi: 10.7759/cureus.2527. Review.

5.

Cardiac birth defects in a twin infant born to a woman with chronic myeloid leukemia on dasatinib.

Hermel DJ, Chiu V, Hermel MH, Tulpule A, Akhtari M.

J Oncol Pharm Pract. 2019 Apr;25(3):699-702. doi: 10.1177/1078155217745710. Epub 2017 Dec 5.

PMID:
29207935
6.

Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.

Leonard JP, Kolibaba KS, Reeves JA, Tulpule A, Flinn IW, Kolevska T, Robles R, Flowers CR, Collins R, DiBella NJ, Papish SW, Venugopal P, Horodner A, Tabatabai A, Hajdenberg J, Park J, Neuwirth R, Mulligan G, Suryanarayan K, Esseltine DL, de Vos S.

J Clin Oncol. 2017 Nov 1;35(31):3538-3546. doi: 10.1200/JCO.2017.73.2784. Epub 2017 Sep 1.

PMID:
28862883
7.

Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States.

Hsi ED, Horwitz SM, Carson KR, Pinter-Brown LC, Rosen ST, Pro B, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta M, Collie AM, Gruver AM, Grzywacz BJ, Turakhia S, Shustov AR, Advani RH, Feldman T, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.

Clin Lymphoma Myeloma Leuk. 2017 Apr;17(4):193-200. doi: 10.1016/j.clml.2016.10.001. Epub 2017 Jan 10.

PMID:
28209473
8.

A prospective cohort study of patients with peripheral T-cell lymphoma in the United States.

Carson KR, Horwitz SM, Pinter-Brown LC, Rosen ST, Pro B, Hsi ED, Federico M, Gisselbrecht C, Schwartz M, Bellm LA, Acosta MA, Shustov AR, Advani RH, Feldman TA, Lechowicz MJ, Smith SM, Lansigan F, Tulpule A, Craig MD, Greer JP, Kahl BS, Leach JW, Morganstein N, Casulo C, Park SI, Foss FM.

Cancer. 2017 Apr 1;123(7):1174-1183. doi: 10.1002/cncr.30416. Epub 2016 Dec 2.

9.

Inactivation of Capicua drives cancer metastasis.

Okimoto RA, Breitenbuecher F, Olivas VR, Wu W, Gini B, Hofree M, Asthana S, Hrustanovic G, Flanagan J, Tulpule A, Blakely CM, Haringsma HJ, Simmons AD, Gowen K, Suh J, Miller VA, Ali S, Schuler M, Bivona TG.

Nat Genet. 2017 Jan;49(1):87-96. doi: 10.1038/ng.3728. Epub 2016 Nov 21.

10.

RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.

Hrustanovic G, Olivas V, Pazarentzos E, Tulpule A, Asthana S, Blakely CM, Okimoto RA, Lin L, Neel DS, Sabnis A, Flanagan J, Chan E, Varella-Garcia M, Aisner DL, Vaishnavi A, Ou SH, Collisson EA, Ichihara E, Mack PC, Lovly CM, Karachaliou N, Rosell R, Riess JW, Doebele RC, Bivona TG.

Nat Med. 2015 Sep;21(9):1038-47. doi: 10.1038/nm.3930. Epub 2015 Aug 24.

11.

p53 expression is a strong marker of inferior survival in de novo diffuse large B-cell lymphoma and may have enhanced negative effect with MYC coexpression: a single institutional clinicopathologic study.

Xie Y, Bulbul MA, Ji L, Inouye CM, Groshen SG, Tulpule A, O'Malley DP, Wang E, Siddiqi IN.

Am J Clin Pathol. 2014 Apr;141(4):593-604. doi: 10.1309/AJCPPHMZ6VHF0WQV.

PMID:
24619762
12.

Proteolytic autodigestion: common tissue pathology in Shwachman-Diamond syndrome?

Kelley JM, Tulpule A, Daley GQ.

Cell Cycle. 2013;12(22):3457-8. doi: 10.4161/cc.26698. Epub 2013 Oct 8. No abstract available.

13.

Pluripotent stem cell models of Shwachman-Diamond syndrome reveal a common mechanism for pancreatic and hematopoietic dysfunction.

Tulpule A, Kelley JM, Lensch MW, McPherson J, Park IH, Hartung O, Nakamura T, Schlaeger TM, Shimamura A, Daley GQ.

Cell Stem Cell. 2013 Jun 6;12(6):727-36. doi: 10.1016/j.stem.2013.04.002. Epub 2013 Apr 18.

14.

Pegylated liposomal doxorubicin, rituximab, cyclophosphamide, vincristine, and prednisone in AIDS-related lymphoma: AIDS Malignancy Consortium Study 047.

Levine AM, Noy A, Lee JY, Tam W, Ramos JC, Henry DH, Parekh S, Reid EG, Mitsuyasu R, Cooley T, Dezube BJ, Ratner L, Cesarman E, Tulpule A.

J Clin Oncol. 2013 Jan 1;31(1):58-64. doi: 10.1200/JCO.2012.42.4648. Epub 2012 Nov 19.

15.

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.

Wilson WH, O'Connor OA, Czuczman MS, LaCasce AS, Gerecitano JF, Leonard JP, Tulpule A, Dunleavy K, Xiong H, Chiu YL, Cui Y, Busman T, Elmore SW, Rosenberg SH, Krivoshik AP, Enschede SH, Humerickhouse RA.

Lancet Oncol. 2010 Dec;11(12):1149-59. doi: 10.1016/S1470-2045(10)70261-8. Epub 2010 Nov 18.

16.

Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy.

Cianfrocca M, Lee S, Von Roenn J, Tulpule A, Dezube BJ, Aboulafia DM, Ambinder RF, Lee JY, Krown SE, Sparano JA.

Cancer. 2010 Aug 15;116(16):3969-77. doi: 10.1002/cncr.25362.

17.

Induction, regulation, and biologic function of Axl receptor tyrosine kinase in Kaposi sarcoma.

Liu R, Gong M, Li X, Zhou Y, Gao W, Tulpule A, Chaudhary PM, Jung J, Gill PS.

Blood. 2010 Jul 15;116(2):297-305. doi: 10.1182/blood-2009-12-257154. Epub 2010 May 4.

18.

Knockdown of Fanconi anemia genes in human embryonic stem cells reveals early developmental defects in the hematopoietic lineage.

Tulpule A, Lensch MW, Miller JD, Austin K, D'Andrea A, Schlaeger TM, Shimamura A, Daley GQ.

Blood. 2010 Apr 29;115(17):3453-62. doi: 10.1182/blood-2009-10-246694. Epub 2010 Jan 20.

19.

KSHV-induced notch components render endothelial and mural cell characteristics and cell survival.

Liu R, Li X, Tulpule A, Zhou Y, Scehnet JS, Zhang S, Lee JS, Chaudhary PM, Jung J, Gill PS.

Blood. 2010 Jan 28;115(4):887-95. doi: 10.1182/blood-2009-08-236745. Epub 2009 Nov 24.

20.

Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet).

Leonard RC, Williams S, Tulpule A, Levine AM, Oliveros S.

Breast. 2009 Aug;18(4):218-24. doi: 10.1016/j.breast.2009.05.004. Epub 2009 Aug 4. Review.

21.

Bendamustine therapy in chronic lymphocytic leukemia.

Masiello D, Tulpule A.

Expert Opin Pharmacother. 2009 Jul;10(10):1687-98. doi: 10.1517/14656560903032698. Review.

PMID:
19527193
22.

Efficient gene knockdowns in human embryonic stem cells using lentiviral-based RNAi.

Tulpule A, Daley GQ.

Methods Mol Biol. 2009;482:35-42. doi: 10.1007/978-1-59745-060-7_3.

PMID:
19089348
23.

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.

Robinson KS, Williams ME, van der Jagt RH, Cohen P, Herst JA, Tulpule A, Schwartzberg LS, Lemieux B, Cheson BD.

J Clin Oncol. 2008 Sep 20;26(27):4473-9. doi: 10.1200/JCO.2008.17.0001. Epub 2008 Jul 14.

PMID:
18626004
24.

Mitotic spindle destabilization and genomic instability in Shwachman-Diamond syndrome.

Austin KM, Gupta ML Jr, Coats SA, Tulpule A, Mostoslavsky G, Balazs AB, Mulligan RC, Daley G, Pellman D, Shimamura A.

J Clin Invest. 2008 Apr;118(4):1511-8. doi: 10.1172/JCI33764.

25.

A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma.

Lim ST, Fayad L, Tulpule A, Modiano M, Cabanillas F, Laffranchi B, Allievi C, Bernareggi A, Levine AM.

Leuk Lymphoma. 2007 Feb;48(2):374-80.

PMID:
17325899
26.
27.

Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma.

Tulpule A, Espina BM, Berman N, Buchanan LH, Smith DL, Sherrod A, Dharmapala D, Gee C, Boswell WD, Nathwani BN, Welles L, Levine AM.

Clin Lymphoma Myeloma. 2006 Jul;7(1):59-64.

PMID:
16879771
28.

Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy.

Levine AM, Tulpule A, Quinn DI, Gorospe G 3rd, Smith DL, Hornor L, Boswell WD, Espina BM, Groshen SG, Masood R, Gill PS.

J Clin Oncol. 2006 Apr 10;24(11):1712-9. Epub 2006 Mar 6.

PMID:
16520466
29.

Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy.

Lim ST, Karim R, Tulpule A, Nathwani BN, Levine AM.

J Clin Oncol. 2005 Nov 20;23(33):8477-82. Epub 2005 Oct 17.

PMID:
16230675
30.

Multidrug resistance in AIDS-related lymphoma.

Tulpule A.

Curr Opin Oncol. 2005 Sep;17(5):466-8. Review.

PMID:
16093797
31.
32.
33.

Ephrin B2 expression in Kaposi sarcoma is induced by human herpesvirus type 8: phenotype switch from venous to arterial endothelium.

Masood R, Xia G, Smith DL, Scalia P, Still JG, Tulpule A, Gill PS.

Blood. 2005 Feb 1;105(3):1310-8. Epub 2004 Oct 7.

PMID:
15471957
34.
35.

Treatment of AIDS related non-Hodgkin's lymphoma with combination mitoguazone dihydrochloride and low dose CHOP chemotherapy: results of a phase II study.

Tulpule A, Espina BM, Pedro Santabarbara AB, Palmer M, Schiflett J, Boswell W, Smith S, Levine AM.

Invest New Drugs. 2004 Jan;22(1):63-8.

PMID:
14707495
36.

Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi sarcoma.

Tulpule A, Groopman J, Saville MW, Harrington W Jr, Friedman-Kien A, Espina BM, Garces C, Mantelle L, Mettinger K, Scadden DT, Gill PS.

Cancer. 2002 Jul 1;95(1):147-54.

37.

Characteristics of indolent non-Hodgkin lymphoma in patients with type 1 human immunodeficiency virus infection.

Levine AM, Sadeghi S, Espina B, Tulpule A, Nathwani B.

Cancer. 2002 Mar 1;94(5):1500-6.

38.

Multidrug resistance (MDR-1) expression in AIDS-related lymphomas.

Tulpule A, Sherrod A, Dharmapala D, Young LL, Espina BM, Sanchez MN, Gill PS, Levine AM.

Leuk Res. 2002 Feb;26(2):121-7.

PMID:
11755462
39.

High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma.

Bi J, Espina BM, Tulpule A, Boswell W, Levine AM.

J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):416-21.

PMID:
11744828
40.

Interleukin 8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma.

Masood R, Cai J, Tulpule A, Zheng T, Hamilton A, Sharma S, Espina BM, Smith DL, Gill PS.

Clin Cancer Res. 2001 Sep;7(9):2693-702.

41.

Clinical aspects and management of AIDS-related Kaposi's sarcoma.

Levine AM, Tulpule A.

Eur J Cancer. 2001 Jul;37(10):1288-95. Review.

PMID:
11423260
42.

Liposomal daunorubicin in the treatment of relapsed or refractory non-Hodgkin's lymphoma.

Tulpule A, Rarick MU, Kolitz J, Bernstein J, Myers A, Buchanan LA, Espina BM, Traynor A, Letzer J, Justice GR, McDonald D, Roberts L, Boswell W, Nathwani B, Levine AM.

Ann Oncol. 2001 Apr;12(4):457-62.

PMID:
11398876
43.

Incidence and management of AIDS-related lymphoma.

Levine AM, Seneviratne L, Tulpule A.

Oncology (Williston Park). 2001 May;15(5):629-39; discussion 639-40, 645-6. Review.

44.

Evolving characteristics of AIDS-related lymphoma.

Levine AM, Seneviratne L, Espina BM, Wohl AR, Tulpule A, Nathwani BN, Gill PS.

Blood. 2000 Dec 15;96(13):4084-90.

PMID:
11110677
45.

Kaposi sarcoma is a therapeutic target for vitamin D(3) receptor agonist.

Masood R, Nagpal S, Zheng T, Cai J, Tulpule A, Smith DL, Gill PS.

Blood. 2000 Nov 1;96(9):3188-94.

PMID:
11050002
47.

Results of a randomized study of IM862 nasal solution in the treatment of AIDS-related Kaposi's sarcoma.

Tulpule A, Scadden DT, Espina BM, Cabriales S, Howard W, Shea K, Gill PS.

J Clin Oncol. 2000 Feb;18(4):716-23.

PMID:
10673512
48.

Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma.

Gill PS, Tulpule A, Espina BM, Cabriales S, Bresnahan J, Ilaw M, Louie S, Gustafson NF, Brown MA, Orcutt C, Winograd B, Scadden DT.

J Clin Oncol. 1999 Jun;17(6):1876-83.

PMID:
10561228
49.

AIDS-related lymphoma.

Tulpule A, Levine A.

Blood Rev. 1999 Sep;13(3):147-50. Review.

PMID:
10527266
50.

Immunotoxin combined with chemotherapy for patients with AIDS-related non-Hodgkin's lymphoma.

Scadden DT, Schenkein DP, Bernstein Z, Luskey B, Doweiko J, Tulpule A, Levine AM.

Cancer. 1998 Dec 15;83(12):2580-7.

PMID:
9874466

Supplemental Content

Loading ...
Support Center